- Home
- NXTC vs APVO Comparison
NXTC vs APVO Comparison
Compare NXTC & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- APVO
- Stock Information
- Founded
- NXTC 2015
- APVO 2016
- Country
- NXTC United States
- APVO United States
- Employees
- NXTC N/A
- APVO N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- APVO Health Care
- Exchange
- NXTC Nasdaq
- APVO Nasdaq
- Market Cap
- NXTC 24.6M
- APVO 21.7M
- IPO Year
- NXTC 2019
- APVO N/A
- Fundamental
- Price
- NXTC $8.71
- APVO $1.49
- Analyst Decision
- NXTC Strong Buy
- APVO
- Analyst Count
- NXTC 3
- APVO 0
- Target Price
- NXTC $23.00
- APVO N/A
- AVG Volume (30 Days)
- NXTC 85.8K
- APVO 930.0K
- Earning Date
- NXTC 11-05-2025
- APVO 11-06-2025
- Dividend Yield
- NXTC N/A
- APVO N/A
- EPS Growth
- NXTC N/A
- APVO N/A
- EPS
- NXTC N/A
- APVO N/A
- Revenue
- NXTC N/A
- APVO N/A
- Revenue This Year
- NXTC N/A
- APVO N/A
- Revenue Next Year
- NXTC N/A
- APVO N/A
- P/E Ratio
- NXTC N/A
- APVO N/A
- Revenue Growth
- NXTC N/A
- APVO N/A
- 52 Week Low
- NXTC $2.69
- APVO $1.32
- 52 Week High
- NXTC $19.20
- APVO $298.00
- Technical
- Relative Strength Index (RSI)
- NXTC 46.50
- APVO 48.65
- Support Level
- NXTC $8.51
- APVO $1.39
- Resistance Level
- NXTC $10.56
- APVO $1.53
- Average True Range (ATR)
- NXTC 1.23
- APVO 0.08
- MACD
- NXTC -0.36
- APVO 0.01
- Stochastic Oscillator
- NXTC 1.93
- APVO 65.79
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.